Recontact can support a new decision when circumstances change. It becomes pressure when the research team simply refuses to accept the first answer.
The direct answer
A patient's decision not to join a clinical trial must be respected. Recontact may be appropriate only when consent, privacy rules, IRB-approved plans, and a meaningful change in information or circumstances support it. Every message should acknowledge the prior decision and provide an easy permanent opt-out.
No is a valid informed outcome.
The purpose of decision support is not universal enrollment. A patient may understand the study, appreciate its potential value, and decide that the risks, uncertainty, burden, timing, or personal priorities do not fit. That decision is not evidence that education failed.
Respect for persons requires voluntary choice. Treating refusal as an obstacle to overcome can turn supportive communication into undue pressure and damage trust far beyond the individual study.
Silence is not permission to intensify outreach.
A missed form, unanswered call, or incomplete pre-screen may reflect uncertainty, overload, changed circumstances, privacy concerns, or a decision not to continue. Teams should define contact limits and opt-out rules before outreach begins.
Repeated messages across channels can feel unavoidable, especially when they appear to come through clinical relationships. The patient should know how their information was obtained, why they are being contacted, and how to stop future contact.
Recontact needs a meaningful reason.
A new site, reduced travel, changed eligibility, amended schedule, new support service, or patient-requested follow-up may justify a new invitation when permitted by the study's approved process. Time alone is not always a sufficient reason.
The message should acknowledge the earlier decision, explain what changed, and ask whether the patient wants new information. It should not imply that reconsideration is expected or that refusal will affect care, relationships, or access to services.
Measure respect, not only reconsideration.
Response and enrollment rates do not show whether the process felt appropriate. Teams should also track opt-outs, complaints, contact frequency, reasons for decline, and patient feedback about pressure, clarity, and control.
A recontact program succeeds when it protects trust and gives patients a clear, low-friction choice. Sometimes the right operational outcome is a permanent no that the system records and honors.
Sources.
- HHS OHRP, The Belmont Report
- FDA, Informed Consent Guidance
- HHS OHRP, Informed Consent FAQs
- Systematic Review of Decision Support for Research Participation
